Originally published as JCO Early Release 10.1200/JCO.2005.07.097 on June 27 2005
Journal of Clinical Oncology, Vol 23, No 22 (August 1), 2005: pp. 5126-5137
© 2005 American Society of Clinical Oncology.
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
Per E. Lønning,
Jürgen Geisler,
Lars E. Krag,
Bjørn Erikstein,
Yngve Bremnes,
Anne I. Hagen,
Ellen Schlichting,
Ernst A. Lien,
Erik S. Øfjord,
Jolanda Paolini,
Anna Polli,
Giorgio Massimini
From the Section of Oncology, Department of Medicine, Haukeland University Hospital; Laboratory for Clinical Biochemistry, Haukeland University Hospital; Center for Clinical Trials, Bergen; Department of Surgery, Rogaland Central Hospital, Stavanger; Department of Oncology, The Norwegian Radiumhospital; Department of Surgery, Ullevaal University Hospital, Oslo; Department of Oncology, University Hospital of North Norway, Tromsø; Department of Surgery, St Olavs Hospital, Trondheim, Norway; and Pharmacia Italia SpA, Pfizer Group, Clinical Development, Milan, Italy
Address reprint requests to Per Eystein Lønning, Section of Oncology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway; e-mail: per.lonning{at}helse-bergen.no
PURPOSE: To evaluate potential detrimental effects of exemestane on bone and lipid metabolism.
PATIENTS AND METHODS: Postmenopausal women with early breast cancer were randomly assigned to exemestane 25 mg daily or placebo for 2 years in a double-blind setting. Primary objective was to evaluate the effect of exemestane on bone mineral density. Secondary objectives were effects on bone biomarkers, plasma lipids, coagulation factors, and homocysteine. Planned size was 128 patients.
RESULTS: One hundred forty-seven patients were enrolled. All patients completed their 24-month visit except for those discontinuing treatment at an earlier stage. The mean annual rate of bone mineral density loss was 2.17% v 1.84% in the lumbar spine (P = .568) and 2.72% v 1.48% in the femoral neck (P = .024) in the exemestane and placebo arm, respectively. The mean change in T-score after 2 years was –0.21 for exemestane and –0.11 on placebo in the hip, and –0.30 and –0.21, respectively, in the lumbar spine. Exemestane significantly increased serum level and urinary excretion of bone resorption, but also bone formation markers. Except for a modest reduction in high-density lipoprotein cholesterol (P < .001) and apolipoprotein A1 (P = .004), exemestane had no major effect on lipid profile, homocysteine levels, or coagulation parameters.
CONCLUSION: Exemestane modestly enhanced bone loss from the femoral neck without significant influence on lumbar bone loss. Except for a 6% to 9% drop in plasma high-density lipoprotein cholesterol, no major effects on serum lipids, coagulation factors, or homocysteine were recorded. Bone mineral density should be assessed according to the US Preventive Services Task Force guidelines.
Supported by Pfizer Inc; P.E.L. and J.G. both received speakers honorarium from Pfizer Inc as well as AstraZeneca and Novartis (the major companies involved in development of aromatase inhibitors), and research support from the same companies.
Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
Related Editorial
- Aromatase Inhibitors and Bone Loss: Risks in Perspective
Charles L. Shapiro
JCO 2005 23: 4847-4849
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
M. Rudas, M. Lehnert, A. Huynh, R. Jakesz, C. Singer, S. Lax, W. Schippinger, O. Dietze, R. Greil, W. Stiglbauer, et al.
Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
Clin. Cancer Res.,
March 15, 2008;
14(6):
1767 - 1774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ponzone, P. Mininanni, E. Cassina, F. Pastorino, and P. Sismondi
Aromatase inhibitors for breast cancer: different structures, same effects?
Endocr. Relat. Cancer,
March 1, 2008;
15(1):
27 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Eastell, J. E. Adams, R. E. Coleman, A. Howell, R. A. Hannon, J. Cuzick, J. R. Mackey, M. W. Beckmann, and G. Clack
Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230
J. Clin. Oncol.,
March 1, 2008;
26(7):
1051 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Kahn
Moving Research From Bench to Bedside to Community: There Is Still More to Do
J. Clin. Oncol.,
February 1, 2008;
26(4):
523 - 526.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Brufsky
Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives
Oncologist,
February 1, 2008;
13(2):
187 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Ariazi, A. Leitao, T. I. Oprea, B. Chen, T. Louis, A. M. Bertucci, C. G.N. Sharma, S. D. Gill, H. R. Kim, H. A. Shupp, et al.
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Mol. Cancer Ther.,
November 1, 2007;
6(11):
2817 - 2827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Jones, J. Cantrell, S. Vukelja, J. Pippen, J. O'Shaughnessy, J. L. Blum, R. Brooks, N. L. Hartung, A. G. Negron, D. A. Richards, et al.
Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy
J. Clin. Oncol.,
October 20, 2007;
25(30):
4765 - 4771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Brufsky, W. G. Harker, J. T. Beck, R. Carroll, E. Tan-Chiu, C. Seidler, J. Hohneker, L. Lacerna, S. Petrone, and E. A. Perez
Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer
J. Clin. Oncol.,
March 1, 2007;
25(7):
829 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Lonning
Reply to 'Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature' by Delea et al.
Ann. Onc.,
January 1, 2007;
18(1):
198 - 199.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Chien and P. E. Goss
Aromatase Inhibitors and Bone Health in Women With Breast Cancer
J. Clin. Oncol.,
November 20, 2006;
24(33):
5305 - 5312.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hirbe, E. A. Morgan, O. Uluckan, and K. Weilbaecher
Skeletal complications of breast cancer therapies.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6309s - 6314s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez, R. G. Josse, K. I. Pritchard, J. N. Ingle, S. Martino, B. P. Findlay, T. N. Shenkier, R. G. Tozer, M. J. Palmer, L. E. Shepherd, et al.
Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17
J. Clin. Oncol.,
August 1, 2006;
24(22):
3629 - 3635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F Labrie
Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
Endocr. Relat. Cancer,
June 1, 2006;
13(2):
335 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Lonning
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
Ann. Onc.,
February 1, 2006;
17(2):
217 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Lonning and J. Geisler
In Reply:
J. Clin. Oncol.,
December 20, 2005;
23(36):
9434 - 9435.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Altundag, O. Altundag, M. Z. Baptista, and S. Akyurek
Heparanase Activity and Bone Loss in Postmenopausal Breast Cancer Patients
J. Clin. Oncol.,
December 1, 2005;
23(34):
8916 - 8917.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Lonning and J. Geisler
In Reply:
J. Clin. Oncol.,
December 1, 2005;
23(34):
8917 - 8918.
[Full Text]
[PDF]
|
|
|
|
